We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Shonit
Punwani
shonit.punwani@uclh.nhs.uk
Mr
Joey
Clemente
joey.clemente@uclh.nhs.uk
Juel
Tuazon
jtuazon@nhs.net
Malignant neoplasms of digestive organsMalignant neoplasms of eye, brain and other parts of central nervous systemMalignant neoplasms of male genital organsMalignant neoplasms of urinary tract
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Metabolic changes related to disease are the precursor to anatomical changes in tissues. Currently our imaging methods routinely used in clinical practice look at the anatomical changes. Whilst these methods are very helpful in making clinical decisions, they are far from being perfect. We miss a lot of early disease because these methods are not sensitive enough. We also sometimes do not know whether what we are looking at is disease or not. And finally we don't really know whether when we see disease it is an aggressive type of disease or non-aggressive.
Hyperpolarised MRI is a new tool that may allow us to address these deficiencies in our current imaging technology. The process of hyperpolarisation allows the production of an injectable solution that can produce signal on a standard MRI scanner that tells us about the metabolism occurring at a particular location. This technology has only just become available for clinical use. We are one of a handful of centres in the world set to evaluate its application in a variety of diseases.
The initial stages of evaluation require us to refine and develop our imaging protocols so that we can assess whether we get consistent results and also so that we can look at where best the potential future clinical use of this technology should be targeted.
Within this application we aim to try out hyperpolarised MRI in a number of different cancers . We will be using 13C-labelled metabolites (for this study 13C-pyruvate) which will allow us to interrogate glucose metabolism. The derangement of glucose metabolism is common to a number of disease processes.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Interventional type: Imaging;
You can take part if:
You may not be able to take part if:
1. Contraindication to MRI (e.g cardiac pacemaker) 2. Contraindication to MR contrast agents 3. Pregnancy 4. Breast feeding 5. Deranged renal function (eGFR< 30)
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Shonit
Punwani
shonit.punwani@uclh.nhs.uk
Juel
Tuazon
jtuazon@nhs.net
Mr
Joey
Clemente
joey.clemente@uclh.nhs.uk
The study is sponsored by University College London and funded by CANCER RESEARCH UK .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 34177
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
